Q-omics provides the consensus-scored SPATA48 profile across patient tissues and cancer cell-line models. SPATA48 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPATA48 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, SPATA48 RNA expression shows 6,335 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, THCA, and HNSC as cancer lineages where SPATA48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA48 survival associations across molecular data types. SPATA48 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA48 RNA expression–survival associations across cancer types. High SPATA48 expression shows unfavorable associations in UVM, LAML and COAD, but favorable associations in ACC, HNSC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPATA48 RNA expression.
This table summarizes SPATA48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA48 shows lower tumor expression in THCA, COAD and BRCA and higher tumor expression in KIRC. The THCA box plot shows higher SPATA48 RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p = .013).
This table shows molecular features associated with SPATA48 in patient tissues and cancer cell lines. In patient samples, SPATA48 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
